Breaking News

Holland Takes 2-0 Lead Over Brazil in World Cup Runner-up Match
Tweet TWEET

CombiMatrix Reports Preliminary Annual Growth in Prenatal Testing Volumes of 172% and 171% for Fourth Quarter and Year,

CombiMatrix Reports Preliminary Annual Growth in Prenatal Testing Volumes of
172% and 171% for Fourth Quarter and Year, Respectively

Company Refocused Commercial Resources on Prenatal and Pediatric Markets
Mid-2012

IRVINE, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for developmental disorders and cancer diagnostics, today announced
that it expects to report record volumes of prenatal testing in the fourth
quarter and year ended December 31, 2012. Preliminary annual growth rates of
172 percent and 171 percent were achieved for billable prenatal tests in the
quarter and full year, respectively. The rapid growth rate in prenatal
testing, which includes both prenatal and miscarriage testing, is the result
of the Company's strategic shift to focus on its prenatal molecular
diagnostics testing markets, where the Company believes that chromosomal
microarray analysis (CMA) is becoming the standard of care. CombiMatrix is the
only publicly-traded company that specializes in CMA. 

R. Judd Jessup, President and CEO of CombiMatrix said, "Our refocused
commercial strategy began to kick in during the latter half of 2012 and
especially in the fourth quarter.We believe our focus on CMA in the prenatal
and pediatric segments is allowing us to gain traction and marketshare as the
technology landscape and standard of care changes. In addition, recent key
clinical publications bolstering that paradigm shift should continue to add
momentum in those markets as 2013 progresses."

Late in 2012, a pair of studies published in the New England Journal of
Medicine, favored CMA over traditional karyotyping for genetic prenatal
diagnosis and genetic evaluation of stillbirths. The two large studies,
published in the December edition of the Journal, represented the largest
head-to-head studies comparing CMA to traditional karyotyping. Both concluded
that CMA identified additional, clinically significant genetic abnormalities
compared to karyotyping in both the prenatal diagnostic setting as well as the
evaluation of stillbirths.

Jessup continued, "CMA gives parents, physicians and educators better tools
for anticipatory care by proactively addressing the impacts of many
chromosomal disorders. In the case of stillbirths or miscarriages, CMA can be
used to determine if there is a genetic reason for these occurrences,
especially when it happens more than once, and can give parents valuable
information about future pregnancies."

Overall billable testing volumes at the Company, including its de-emphasized
oncology segment, was also up strongly in the period, growing 21 percent and
25 percent in the quarter and full year, respectively, over 2011. CombiMatrix
expects to report its operating results in late February, 2013 and file its
annual report for 2012 on Form 10-K in mid-March, 2013. The Company will issue
a press release and hold an investor conference call to discuss results.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix
Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory
which offers DNA-based testing services to the prenatal, pediatric and
oncology markets. The Company performs genetic testing utilizing Microarray,
FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric
testing services for the detection of abnormalities of genes at the DNA level
beyond what can be identified through traditional technologies. CMDX was also
the first commercial clinical laboratory in the United States to make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals. Additional information about CMDX is available at
www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and include, but are
not limited to, statements regarding the advantages and efficacy of CMA over
standard karyotyping, the market momentum for CMA, the impact of our CMA focus
on market share, and our preliminary report of prenatal testing volumes. These
forward-looking statements are not guarantees of future results and are
subject to risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in any
forward-looking statement. The risks and uncertainties referred to above
include, but are not limited to: the risk that our final reported prenatal
testing volumes are different from this preliminary report; market acceptance
of CMA as a preferred method over karyotyping; the rate of transition to CMA
from karyotyping; our ability to successfully expand the base of our customers
and strategic partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related reports, optimize
the reimbursements received for our testing services, and increase operating
margins by improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer rosters in
both developmental medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets; changes in
demand for our future products; legislative, regulatory and competitive
developments; general economic conditions; and various other factors. Further
information on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q,
and in other filings with the Securities and Exchange Commission. We undertake
no obligation to revise or update publicly any forward-looking statements for
any reason, except as required by law.

CONTACT: Company Contact:
         R. Judd Jessup
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
        
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com
        
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

CombiMatrix Corporation